Dabigatran-ethyl-ester-hydrochloride - Thrombin 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDabigatran ethyl ester hydrochlorideCat. No.: HY-77521CAS No.: 211914-50-0分式: CHClNO分量: 536.03作靶點(diǎn): Thrombin作通路: Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 m

2、g/mL (93.28 mM)H2O : 5 mg/mL (9.33 mM; Need ultrasonic)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.8656 mL 9.3278 mL 18.6557 mL5 mM 0.3731 mL 1.8656 mL 3.7311 mL10 mM 0.1866 mL 0.9328 mL 1.8656 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)

3、動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (4.66 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (4.66 mM);

4、 Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (4.66 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Dabigatran ethyl ester hydrochloride有效地核糖 氫煙酰胺脫氫酶(NQO2)抑制劑，IC50值為0.8 M；也 凝酶的抑制劑。IC50 & Target IC50: 0.8 M (NQO2) 1體外研究 The Ki of da

5、bigatran (ethyl ester hydrochloride) toward NQO2 is 0.9 M and the IC50 is 0.8 M. The ethylester group of dabigatran (ethyl ester hydrochloride) significantly extends the interaction surface especiallywith hydrophobic amino acids such as Ile 128 and Met 154. Dabigatran ethyl ester has higher affinity

6、 thanDabigatran to both thrombin and NQO2 1. Dabigatran is a highly selective, reversible, and potent thrombininhibitor and is orally available as the prodrug, dabigatran etexilate 2.體內(nèi)研究 Dabigatran (Ki=4.5 nM) could bind to human thrombin selectively, and reversibly to realize a strong and long-las

7、ting anticoagulant effect 3.PROTOCOLKinase Assay 1 NQO2 (0.5 M) is incubated with the substrate mitomycin C (50 M) and four different Dabigatranconcentrations in 100 mM potassium phosphate buffer (pH 5.8) at room temperature for 5 min prior to theaddition of NADH (in increasing concentrations) as a

8、cosubstrate and photometric monitoring at 340 nm for30 min at rt. Ki values are determined. Data generated are used to calculate the IC50 of inhibition of NQO2activity 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Biochem Pharmacol. 2016

9、 Nov 1;119:76-84.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Michaelis S, et al. Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2). J MedChem. 2012 Apr 26;55(8):3934-44.2. Eisert WG, et al. Dabigatran: an oral novel

10、potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010Oct;30(10):1885-9.3. Hauel NH, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002 Apr 25;45(9):1757-66.McePdfHeight2/2 Master of Small Molecules 您邊的抑制劑師www.MedChemECaution: Product has not been fully valid